Grifols (GRFS) hosted it 2025 Capital Markets Day on February 27 in London, where the company announced it would double revenue to EUR 14 billion over the next decade as part of an ambitious ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

Sorry, there were no product categories that matched your search term. To improve our service and ensure this does not happen in the future, please take a moment to ...

Grifols expects to boost revenue and free cash flow, shares soar Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the ...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...